70 related articles for article (PubMed ID: 23846207)
21. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
John GT; Manivannan J; Chandy S; Peter S; Fleming DH; Chandy SJ; Balakrishnan N; Krishnamurthy K; Kirubakaran MG; Jacob CK
Transplant Proc; 2005 Dec; 37(10):4303-5. PubMed ID: 16387103
[TBL] [Abstract][Full Text] [Related]
22. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation.
Jeon S; Lee WK; Lee Y; Lee DG; Lee JW
Ophthalmology; 2012 Sep; 119(9):1892-8. PubMed ID: 22657564
[TBL] [Abstract][Full Text] [Related]
24. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
25. Oral ganciclovir for cytomegalovirus retinitis.
Torgovnick J
N Engl J Med; 1996 Jan; 334(1):55-6. PubMed ID: 7494578
[No Abstract] [Full Text] [Related]
26. Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. The Foscarnet Italian Study Group.
Carosi G; Castelli F; Lernestedt JO; Antoniazzi E; Gerna G
AIDS; 1997 Feb; 11(2):258-60. PubMed ID: 9030380
[No Abstract] [Full Text] [Related]
27. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
28. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Chou S; Miner RC; Drew WL
J Infect Dis; 2000 Dec; 182(6):1765-8. PubMed ID: 11069251
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and therapeutic challenges.
Tauqir MZ; Shulman M; Bittencourt M; Sepah YJ; Ibrahim M; Do DV; Nguyen QD; Foster CS; Vora RA; Albini TA
Retina; 2013 Apr; 33(4):883-8. PubMed ID: 23446654
[No Abstract] [Full Text] [Related]
30. Intraocular therapy for cytomegalovirus retinitis.
Palestine AG
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):25-8. PubMed ID: 11363527
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus Retinitis during Maintenance Therapy in child with Acute Lymphoblastic Leukemia.
Shah MS; Rahman AA; Begum M; Kibria CH; Begum F
Mymensingh Med J; 2019 Apr; 28(2):465-469. PubMed ID: 31086168
[TBL] [Abstract][Full Text] [Related]
32. Leflunomide in renal transplantation.
Chon WJ; Josephson MA
Expert Rev Clin Immunol; 2011 May; 7(3):273-81. PubMed ID: 21595593
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and therapeutic challenges.
Chhablani JK; Mathai A; Reddy R; Jalali S; Stepien K; Albini T
Retina; 2011 Oct; 31(9):1963-6. PubMed ID: 21734623
[No Abstract] [Full Text] [Related]
34. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
Martin DF; Kuppermann BD; Wolitz RA; Palestine AG; Li H; Robinson CA
N Engl J Med; 1999 Apr; 340(14):1063-70. PubMed ID: 10194235
[TBL] [Abstract][Full Text] [Related]
35. [Intravitreal ganciclovir in cytomegalovirus retinitis in AIDS].
Olea JL; Salvat M; Mateos JM; Vila J; Villalonga C; Riera M
Rev Clin Esp; 1996 Apr; 196(4):208-12. PubMed ID: 8701057
[TBL] [Abstract][Full Text] [Related]
36. FDA panel unanimously recommends approval of Vistide for CMV retinitis. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50. PubMed ID: 11363532
[TBL] [Abstract][Full Text] [Related]
37. Leflunomide in solid organ transplantation and polyoma virus infection.
Josephson MA; Javaid B; Kadambi PV; Meehan SM; Williams JW
Adv Exp Med Biol; 2006; 577():255-65. PubMed ID: 16626041
[No Abstract] [Full Text] [Related]
38. Sevirumab. Protovir, MSL 109, EV2 7, SDZ MSL 109.
Drugs R D; 1999 Nov; 2(5):315-7. PubMed ID: 10728470
[No Abstract] [Full Text] [Related]
39. Use of leflunomide in human renal transplantation.
Pascual J; Orte J; Marcén R; Burgos J; Ortuño J
Transplantation; 2001 Nov; 72(10):1709. PubMed ID: 11726839
[No Abstract] [Full Text] [Related]
40. Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure.
Mossad SB; Avery RK
Transpl Infect Dis; 2007 Sep; 9(3):260; author reply 260-1. PubMed ID: 17605734
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
